Monoclonal antibody pharmacokinetics and pharmacodynamics
- PMID: 18784655
- DOI: 10.1038/clpt.2008.170
Monoclonal antibody pharmacokinetics and pharmacodynamics
Abstract
More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US Food and Drug Administration, and it is quite likely that the number of approved antibodies will double in the next 7-10 years. Antibody drugs show several desirable characteristics, including good solubility and stability, long persistence in the body, high selectivity and specificity, and low risk for bioconversion to toxic metabolites. However, many antibody drugs demonstrate attributes that complicate drug development, including very poor oral bioavailability, incomplete absorption following intramuscular or subcutaneous administration, nonlinear distribution, and nonlinear elimination. In addition, antibody administration often leads to an endogenous antibody response, which may alter the pharmacokinetics and efficacy of the therapeutic antibody. Antibodies have been developed for a wide range of disease conditions, with effects produced through a complex array of mechanisms. This article attempts to provide a brief overview of the main determinants of antibody pharmacokinetics and pharmacodynamics. Clinical Pharmacology & Therapeutics (2008); 84, 5, 548-558 doi:10.1038/clpt.2008.170.
Similar articles
-
[The pharmacokinetics of monoclonal antibodies].Ned Tijdschr Geneeskd. 2007 Mar 24;151(12):683-8. Ned Tijdschr Geneeskd. 2007. PMID: 17447593 Review. Dutch.
-
Elimination mechanisms of therapeutic monoclonal antibodies.Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X. Drug Discov Today. 2006. PMID: 16478695 Review.
-
Drug interaction studies of therapeutic proteins or monoclonal antibodies.J Clin Pharmacol. 2007 Dec;47(12):1540-54. doi: 10.1177/0091270007308616. Epub 2007 Oct 25. J Clin Pharmacol. 2007. PMID: 17962422 Review.
-
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.Int Immunopharmacol. 2008 Mar;8(3):477-83. doi: 10.1016/j.intimp.2007.12.004. Epub 2008 Jan 11. Int Immunopharmacol. 2008. PMID: 18279802
-
Clinical pharmacokinetics of therapeutic monoclonal antibodies.Clin Pharmacokinet. 2010 Aug;49(8):493-507. doi: 10.2165/11531280-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608753 Review.
Cited by
-
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.BioDrugs. 2022 Nov;36(6):731-748. doi: 10.1007/s40259-022-00559-1. Epub 2022 Oct 31. BioDrugs. 2022. PMID: 36315391 Free PMC article. Review.
-
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2169-2179. doi: 10.1007/s00259-016-3442-1. Epub 2016 Jun 25. Eur J Nucl Med Mol Imaging. 2016. PMID: 27342417 Free PMC article.
-
Low-molecular weight inhibitors of the alternative complement pathway.Immunol Rev. 2023 Jan;313(1):339-357. doi: 10.1111/imr.13143. Epub 2022 Oct 11. Immunol Rev. 2023. PMID: 36217774 Free PMC article. Review.
-
A strategy for risk mitigation of antibodies with fast clearance.MAbs. 2012 Nov-Dec;4(6):753-60. doi: 10.4161/mabs.22189. MAbs. 2012. PMID: 23778268 Free PMC article.
-
Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.J Med Chem. 2015 Jun 11;58(11):4665-77. doi: 10.1021/acs.jmedchem.5b00220. Epub 2015 May 22. J Med Chem. 2015. PMID: 25973614 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
